A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Safety and tolerability of a single dose intravenous bolus injection of Sildenafil in
patients with moderate to severe cirrhosis and kidney disease will be determined.
Phase:
Phase 1
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore